Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations

Go back to Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) Delayed: 101.94 --0 (-0%)
Previous Close $101.94    52 Week High $101.99 
Open $3.23    52 Week Low $58.50 
Day High $101.94    P/E N/A 
Day Low $101.94    EPS $-0.27 
Volume 3,714